Anti-HPV16E7 protein monoclonal antibody 69A6, hybridoma cells, and preparation method and application of anti-HPV16E7 protein monoclonal antibody 69A6

By developing the anti-HPV16E7 protein monoclonal antibody 69A6 and its hybridoma cells, we have solved the diagnostic difficulties in the existing technology when HR-HPV DNA is positive, achieved high-sensitivity detection of early-stage cervical cancer, and reduced the burden of examinations.

CN111333719AActive Publication Date: 2020-06-26SOUTHWEST UNIV
6 Cites 5 Cited by

Patent Information

Application Number
CN202010179913.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2020-03-16
Publication Date
2020-06-26
Estimated Expiration
2040-03-16

AI Technical Summary

Technical Problem

Existing cervical cancer screening methods lack clear treatment plans when HR-HPV DNA tests are positive, resulting in the trauma and psychological and economic burden of colposcopy, and are unable to early warn and diagnose cervical cancer, especially in CIN1, CIN2, and CIN3 Wait for the early stages.

Method used

Developed the anti-HPV16E7 protein monoclonal antibody 69A6 and its hybridoma cells. Through hybridoma technology screening and purification, high-titer monoclonal antibodies were obtained for quantitative detection of HPV16E7 protein, preparation of ELISA kits, etc., achieving specificity for HPV16E7 protein. Highly accurate and sensitive detection.

Benefits of technology

This technology can provide important significance in the early diagnosis of cervical cancer. Through highly sensitive and specific detection, it helps to detect cervical cancer cells early, reducing unnecessary examination frequency and patient burden.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an anti-HPV16E7 protein monoclonal antibody 69A6, hybridoma cells, and a preparation method and application of the anti-HPV16E7 protein monoclonal antibody 69A6. The hybridomacells are preserved in the China Center for Type Culture Collection, and a preservation number is CCTCC NO: C201720. The hybridoma cells can secrete the monoclonal antibody with high titer, and the obtained antibody can react with HPV16-positive cell lines CaSki and HPV16-positive cervical cancer squamous cell carcinoma paraffin tissue sections, has good specificity, and can be used as ELISA kits,immunochemistry kits or immunofluorescence kits.
Need to check novelty before this filing date? Find Prior Art